Developments in the treatment of parkinson's disease

Drug and Therapeutics Bulletin

Volumn 37, Issue 5, 1999, Pages 36-40

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CO BENELDOPA; CO CARELDOPA; ENTACAPONE; LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; TOLCAPONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DIARRHEA; DRUG CHOICE; DYSKINESIA; HALLUCINATION; HUMAN; META ANALYSIS; NAUSEA; PARKINSON DISEASE; SHORT SURVEY; THALAMOTOMY; XEROSTOMIA;

EID: 0033390290     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.1999.37536     Document Type: Short Survey

References (64)

1. Drugs for Parkinson's disease reviewed. DTB 1995; 33: 49-52.
2. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 672-81.
3. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991; 41: 202-5.
4. Rajput AH, Uitti RJ, Rajput AH, Offord KP. Timely levodopa (LD) administration prolongs survival in Parkinson's disease. Parkinsonism Relat Disord 1997; 3: 159-65.
5. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 1987; 22: 8-12.
6. Block G, Liss C, Reines S, Irr J, Nibbelink D and the CR First Study Group. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. Eur Neurol 1997; 37: 23-7.
7. Dupont E, Andersen A, Boas J et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de nova parkinsonian patients. Acta Neurol Scand 1996; 93: 14-20.
8. Nutt JG. Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease. Lancet 1998; 351: 1221-2.
9. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996; 60: 36-40.
10. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997; 42: 747-55.
11. Entacapone. Summary of product characteristics, EU. Orion Corporation, November 1998.
12. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996; 39: 29-36.
13. Lees AJ on behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995; 311: 1602-7.
14. Ben-Shlomo Y, Churchyard A, Head J et al. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. BMJ 1998; 316: 1191-6.
15. Abrams KR. Monitoring randomised controlled trials. BMJ 1998: 316: 1183-4 [editorial].
16. Breteler MMB. Selegiline, or the problem of early termination of clinical trials. BMJ 1998; 316: 1182-3 [editorial].
17. Olanow CW, Fahn S, Langston JW, Godbold J. Selegiline and mortality in Parkinson's disease. Ann Neurol 1996; 40: 841-5.
18. Olanow CW, Myllylä W, Sotaniemi KA et al. Effect of selegiline on mortality in patients with Parkinson's disease. A meta-analysis. Neurology 1998; 51: 825-30.
19. Thorogood M, Armstrong B, Nichols T, Hollowell J. Mortality in people taking selegiline: observational study. BMJ 1998; 317: 252-4.
20. Selegiline hydrochloride. Summary of product characteristics, UK. Athena Neurosciences, September 1998.
21. 3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 1996; 312: 35-44.
22. Poewe W. Should treatment of Parkinson's disease be started with a dopamine agonist? Neurology 1998; 51 (suppl 2): S21-4.
23. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993; 307: 469-72.
24. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994; 57: 1034-8.
25. Factor SA, Weiner WJ. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov Disord 1993; 8: 257-62.
26. Weiner WJ, Factor SA, Sanchez-Ramos JR et al. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 1993; 43: 21-7.
27. Giménez-Roldán S, Tolosa E, Burguera JA, Chacón J, Liaño H, Forcadell F. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Clin Neuropharmacol 1997; 20: 67-76.
28. Przuntek H, Welzel D, Gerlach M et al. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J Neural Transm 1996; 103: 699-715.
29. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987; 37: 826-8.
30. Hely MA, Morris JGL, Reid WGJ et al. The Sydney multicentre study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994; 57: 903-10.
31. Clarke CE, Speller JM. Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease (Cochrane Review). In: The Cochrane Library, Issue 1, 1999. Oxford: Update Software.
32. Chaudhuri KR, Clough C. Subcutaneous apomorphine in Parkinson's disease. BMJ 1998; 316: 641 [editorial].
33. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 573-6.
34. 2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol 1998; 21: 101-7.
35. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. JAMA 1997; 278: 125-30.
36. Rinne UK, Bracco F, Chouza C et al and the PKDS009 Study Group. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs 1998; 55(suppl 1): 23-30.
37. Rinne UK, Bracco F, Chouza C et al and the PKDS009 Collaborative Study Group. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997; 48: 363-8.
38. Sethi KD, O'Brien CF, Hammerstad JP et al for the Ropinirole Study Group. Ropinirole for the treatment of early Parkinson disease. Arch Neurol 1998; 55: 1211-6.
39. Hubble JP, Koller WC, Cutler NR et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995; 18: 338-47.
40. Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F on behalf of the 056 Study Group. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. Mov Disord 1998; 13: 39-45.
41. Shannon KM, Bennett JP, Friedman JH for the Pramipexole Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997; 49: 724-8.
42. R 42. Lieberman A, Imke S, Muenter M et al. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. Neurology 1993; 43: 1981-4.
43. Hutton JT, Koller WC, Ahlskog JE et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology 1996; 46: 1062-5.
44. Steiger MJ, El-Debas T, Anderson T, Findley LJ, Marsden CD. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol 1996; 243: 68-72.
45. Inzelberg R, Nisipeanu P, Rabey JM et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996; 47: 785-8.
46. Guttman M and the International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology 1997; 49: 1060-5.
47. Lieberman A, Ronhosky A, Korts D et al. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997; 49: 162-8.
48. Wermuth L and the Danish Pramipexole Study Group. A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease. Eur J Neurol 1998; 5: 235-42.
49. Adler CH, Sethi KD, Hauser RA et al for the Ropinirole Study Group. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997; 49: 393-9.
50. Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's diease. Clin Neuropharmacol 1996; 19: 234-45.
51. Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol O, Stocchi F on behalf of the 053 Study Group. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. Mov Disord 1998; 13: 46-51.
52. Larsen JP, Brunt E, Korczyn AD, Nagy Z, Poewe W, Ruggien S and the 059 Study Group. Ropinirole is effective in long-term treatment of patients with early Parkinson's disease. Neurology 1998; 50 (suppl 4): A277-8 [abstract P05.042].
53. Committee for Proprietary Medicinal Products (CPMP). European Public Assessment Report. Mirapexin. London: European Medicines Evaluation Agency, 1999.
54. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998; 50: 1323-6.
55. Tasker RR. Thalamotomy. Neurosurg Clin N Am 1990; 1: 841-64.
56. Perry VL, Lenz FA. Ablative therapy for movement disorders. Thalamotomy for Parkinson's disease. Neurosurg Clin N Am 1998; 9: 317-23.
57. Robert G, Stevens A. Pallidotomy for Parkinson's disease. Wessex Institute of Public Health Medicine. 1996, March. Development and Evaluation Committee Report No. 51.
58. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 1992; 76: 53-61.
59. Lozano AM, Lang AE, Galvez-Jimenez N et al. Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet 1995; 346: 1383-7.
60. Lozano AM, Lang AE. Pallidotomy for Parkinson's disease. Neurosurg Clin N Am 1998; 9: 325-36.
61. Benabid AL, Pollak P, Gervason C et al. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 1991; 337: 403-6.
62. Benabid AL, Pollak P, Goa D et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg 1996; 84: 203-14.
63. Limousin P, Pollak P, Benazzouz A et al. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995; 345: 91-5.
64. Limousin P, Krack P, Pollak P et al. Electrical Stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998; 339: 1105-11.